The true clinical utility of quantitative fetal fibronectin.
Faron et al.'s dismissal of fFN in screening asymptomatic women is based on a flawed assumption that positive likelihood ratios (PLR) < 10 and negative likelihood ratios (NLR) > 0.1 are not valuable, and on evaluation of qualitative fFN only. We would argue that there is ample evidence to support its use in asymptomatic high-risk women and in threatened preterm labour when used in its quantitative form, not analysed in this meta-analysis.